Mendota Financial Group LLC Sells 309 Shares of AstraZeneca PLC (NASDAQ:AZN)

Mendota Financial Group LLC trimmed its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 15.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,680 shares of the company’s stock after selling 309 shares during the period. Mendota Financial Group LLC’s holdings in AstraZeneca were worth $110,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. McClarren Financial Advisors Inc. raised its holdings in shares of AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares during the period. GHP Investment Advisors Inc. purchased a new stake in AstraZeneca in the second quarter worth $26,000. Capital Performance Advisors LLP bought a new stake in shares of AstraZeneca during the third quarter worth $28,000. Groupama Asset Managment boosted its stake in shares of AstraZeneca by 22.9% during the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after purchasing an additional 101,225 shares during the period. Finally, Ashton Thomas Securities LLC bought a new position in shares of AstraZeneca in the third quarter worth about $45,000. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Price Performance

AZN opened at $65.73 on Tuesday. The firm has a market capitalization of $203.80 billion, a PE ratio of 31.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The business’s 50-day moving average is $66.00 and its two-hundred day moving average is $74.78. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.87 EPS. Research analysts anticipate that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AZN has been the subject of several research reports. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, AstraZeneca has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.